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Neonates and young children remain susceptible to many serious infectious diseases preventable through vaccination.
In general, current vaccines strategies to prevent infectious diseases are unable to induce protective levels of antibodies in
the first 6 months of life. Women vaccinated during pregnancy are capable of producing immunoglobulin antibodies that
are transported actively to the fetus, and maternal immunization can benefit both the mother and the child. With few
exceptions, maternal immunization is not a routine, because of the concerns related to the safety of this intervention. Ethical
and cultural issues make the studies on maternal immunization difficult; however, in the last decade, the development of
new vaccines, which are very immunogenic and safe has reactivated the discussions on maternal immunization.
In this paper we present a review of the literature about maternal immunization based on MEDLINE data (1990 to
2002).
The most important conclusions are: 1) there is no evidence of risk to the fetus by immunizing pregnant women with
toxoids, polysaccharide, polysaccharide conjugated and inactive viral vaccines; 2) most viral attenuated vaccines are
probably safe too, but data is still insufficient to demonstrate their safety; therefore these vaccines should be avoided in
pregnant women; 3) in Brazil, there is a need for a maternal immunization program against tetanus.
Many new candidate vaccines for maternal immunization are available, but studies should be conducted to evaluate
their safety and efficacy, as well as regional priorities based on epidemiological data.
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Immunization is considered one of
the most important measures to control
infectious diseases and the recommen-
dations for routine immunization are
based on the analysis of risks, benefits
and cost of immunobiologicals1,2 . De-
spite the huge impact of immunization
programs on the reduction of morbid-
ity and mortality associated with vac-
cine preventable diseases, newborns
and breast-feeding babies remain vul-
nerable to several diseases caused by
viruses and bacteria1-24.
The immune system of breast-feed-
ing babies is not mature enough to re-
spond to some types of immunobio-
logicals and, even when vaccines are
administered in the first few months of
life, a latency period is required to ob-
tain antibody titers in sufficient
amounts to confer protection on the
child. Another concern is the possibil-
ity that the antibodies acquired pas-
sively from the mother could affect the
response to vaccines containing live
attenuated viruses3-10.
Pregnancy offers an excellent op-
portunity to increment mothers’ and
babies’ immunity. Pregnant women are
capable of producing suitable amounts
of antibodies and the transfer of such
antibodies to the fetus through the pla-
centa occurs during the last 4 to 6
weeks of pregnancy9. Most IgG class
antibodies are capable of crossing the
placenta barrier. The concentration of
subclass IgG1 antibodies can be higher
in the cord blood than in maternal
blood, thus suggesting that there is an
active transfer of antibodies in the pla-
centa9. The antibodies acquired pas-
sively by the child can confer protec-
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tion on the newborn against a variety
of serious diseases3-10.
Until the 1960’s, knowledge about
the possible deleterious effects of the
products administered to pregnant
women on fetuses was very limited,
and many vaccines were administered
to pregnant women. In the United
States, from 1957 to 1966 vaccines
against influenza and poliomyelitis
were routinely administered in mater-
nal immunization programs. Results
from a major seven-year study nation-
wide (Collaborative Perinatal Project)
involving more than 50,000 pregnant
women and their children, where oc-
currences such as malformations, learn-
ing disorders, hearing deficiency and
risk of neoplasias were investigated,
demonstrated that the vaccines against
poliomyelitis (oral and inactivated),
influenza, diphtheria, tetanus and
smallpox did not have adverse conse-
quences for mother or fetus7,9.
After verifying the deleterious ef-
fects of thalidomide on babies from
pregnant women who had taken that
drug, a deep concern was aroused over
the safety of pharmaceutical drug use
(including vaccines and immuno-
globulins) during pregnancy. Despite
no evidence of risk of malformation
being associated with vaccines, there
is great fear that immunobiologicals
can cause some type of harmful effect
on the fetus. Therefore, whenever pos-
sible, vaccines recommended for preg-
nant women should be administered in
the latter stages of pregnancy, when
the fetus has already formed. This step
seeks to prevent that any malforma-
tions and abortions that may occur, ir-
respective of vaccination, be ascribed
to the vaccines3-10.
The difficulties in conducting stu-
dies in pregnant women limit the
evaluation of the results due to the
small number of cases. However, many
women of childbearing potential were
vaccinated before knowing they were
pregnant, and the follow-up of these
women and their children has pro-
duced important information on vac-
cine safety both for mother and baby.
In addition, in the past decade the de-
velopment of increasingly safer and
more immunogenic vaccines against
several infectious agents that cause se-
rious diseases in breast-feeding babies
has reawakened discussions about the
risks and benefits of vaccinating preg-
nant women, particularly where there
is a high risk that the pregnant woman
and/or fetus develop infection with se-
rious consequences3-10.
In this study we present revised
data from the literature about the in-
dications and contraindications of the
use of vaccine and immunoglobulins
by pregnant women, through the sur-
veying of publications on the subject
issued over the past 10 years.
Considerations of the advantages
and disadvantages of maternal
immunization
Newborns belong to a group which
is highly vulnerable to several viral and
bacterial infections1,11-18. Since, for the
most part, vaccines are recommended
for breast-feeding infants on three-dose
schemes, at 2, 4 and 6 months, before
the sixth month of life children are un-
protected, or only partially protected
against vaccine preventable diseases1,3-10.
The vaccination of pregnant women
could overcome this difficulty, confer-
ring passive protection on the baby and
affording a valuable opportunity to
provide mother and child with immu-
nity. The best example of the efficacy
of this measure is the disappearance of
neonatal tetanus in developed countries,
where routine vaccination of pregnant
women against tetanus has been a com-
mon practice for several decades3-10.
In industrialized countries, group B
Streptococcus and gram-negative en-
terobacteria are the main bacterial
agents for serious neonatal infec-
tions14,20,21.
Except for the neonatal period,
during the first 6 months of life the
Streptococcus pneumoniae is the main
bacterial agent for pneumonias and
bacteremias in most countries1,14. Al-
though the S. pneumoniae rarely
causes sepsis in the neonatal period,
171 cases of neonatal sepsis by that
bacterium were identified in the USA;
in cases of early development sepsis
(< 48 hours) the prognostic and death
rate were higher than in cases of late
development sepsis20.
Whereas infections by
Haemophilus influenzae type b have
virtually disappeared in developed
countries, in developing countries that
bacterium is still responsible for a
large number of pneumonia, meningi-
tis, bacteremia and sepsis cases in chil-
dren under 5, particularly in non
breast-feeding infants1,14.
The prevalence of infections
caused by Neisseria meningitidis
varies largely, being higher in popu-
lations living in poor conditions; nev-
ertheless, even in developed countries
these infections present high rates of
morbidity and mortality in breast-feed-
ing babies14,22,23.
Among viral infections are to be
included those caused by the respira-
tory syncytial virus and rotavirus, re-
spectively the most important agents
for respiratory disease and gastroen-
teritis in breast-feeding babies. The vi-
ruses of influenza, parainfluenza, her-
pes simplex, cytomegalovirus and en-
terovirus are also an important cause
of morbidity among breast-feeding ba-
bies15-19.
 The objective of maternal immu-
nization is to afford newborns and
breast-feeding babies sufficient quan-
tities of specific antibodies against the
pathogens that cause serious infec-
tions during this highly vulnerable pe-
riod2-10.
During pregnancy, women are capa-
ble of producing sufficient quantities
of antibodies. Although class IgM, IgA,
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IgD and IgE antibodies do not cross the
placenta, class IgG antibodies can be
actively transferred to the fetus through
the placenta. The half-life of maternal
antibodies is 3 to 4 weeks and the per-
sistence of these antibodies depends on
the initial titers. Typically, after 6
months of age, maternal antibodies
have already disappeared or are present
in low titers; however, during the sec-
ond semester of life, children who have
been suitably immunized already
present their own antibodies against
vaccine antigens. Women vaccinated
during pregnancy can also transfer spe-
cific antibodies against several patho-
genic agents through the colostrum and
maternal milk and, in this case, there is
also a transfer of IgA class antibodies
in addition to that of IgG9.
The main difficulties in imple-
menting vaccination programs for
pregnant women as a public health in-
tervention relate to the theoretical con-
siderations over the potential risks of
vaccines for pregnant women and fe-
tus, the relatively limited knowledge
in that field and the technical, ethical
as well as legal difficulties in conduct-
ing studies on the risks and benefits of
vaccination for pregnant women2-10.
The potential risks of maternal im-
munization are, generally speaking,
the same as those for the population,
and are directly related to the specific
product. However, during this period
there is a concern that the occurrence
of adverse events could have implica-
tions on the course of the pregnancy
or induce premature labor. The expe-
rience with the vaccines habitually
recommended for maternal immuniza-
tion offers no backup for this concern;
still, it is recommended that vaccina-
tion during the first trimester of preg-
nancy be avoided1-10.
The main disadvantages of mater-
nal immunization include absence of
the benefits of this measure when there
is premature birth, the potential risk
that the mother’s antibodies would af-
fect the immunological response of the
newborn, whether by inducing immu-
nological tolerance or by inactivating
certain vaccines containing live at-
tenuated viruses. In the first situation,
one should consider that the produc-
tion of maternal antibodies after vac-
cination is not immediate and that the
transfer of maternal antibodies to the
fetus only occurs in the last 4 to 6
weeks of pregnancy8,9.
Situation of vaccine preventable
diseases in Brazil
Over the past 20 years there has
been a sharp reduction in the number
of cases of some vaccine preventable
diseases in Brazil, mainly due to in-
creased vaccine coverage and to the
introduction of mass vaccination cam-
paigns. While some diseases were
gradually disappearing, others were
recognized as being important for pub-
lic health (Table 1).
The best example of the impact
that vaccination had on disease reduc-
tion is poliomyelitis, which was elimi-
nated from this country after the intro-
duction of mass vaccination cam-
paigns in the 1980’s. The last case of
paralytic polio in Brazil was registered
in 1989. An inverse example is tuber-
culosis, which persists as a major pub-
lic health issue despite the excellent
vaccine coverage. The tuberculosis
vaccine is quite effective in the pre-
vention of serious forms of the disease,
e.g. tuberculous meningitis; however,
to control this disease other measures
are necessary besides vaccination.
Despite the substantial reduction
in cases of diphtheria, tetanus and
whooping cough in the year 2001, 19
cases of diphtheria (3 deaths), 1,464
cases of whooping cough (13 deaths),
366 cases of accidental tetanus (86
deaths) and 34 cases of neonatal teta-
nus (27 deaths) were registered. The
death rates for these diseases are con-
siderably high, reaching 79% in cases
of neonatal tetanus23.
In 1997 there was a measles epi-
demic in Brazil, with 53,664 cases and
61 deaths.
After a national vaccination cam-
paign against measles and reinforced
actions for epidemic surveillance, cir-
culation of the measles virus in Brazil
was finally interrupted, with only 1
case being diagnosed in 2001 and an-
other in 2002, both imported from Ja-
pan. With regard to rubella, up until
the mid-nineties information on its in-
Table 1 - Number of notified cases of some vaccine preventable diseases in Brazil,
in 1982 and 2000, according to the Ministry of Health.
Compulsory notification diseases 1982 2000
Hepatitis B ? 6,396
Tuberculosis 87,822 93,360
Diphtheria 3,297 58
Accidental Tetanus 2,226 525
Neonatal Tetanus 584 41
Whooping Cough 54,766 2,464
Haemophilus influenzae type b meningitis ? 577
Measles 39,370 36
Rubella ? 14,767
Congenital Rubella Syndrome ? 79
Yellow Fever 24 85
Meningococcal Disease 1,226 4,592
Human Rabies 127 26
Hepatitis A ? 20,310
Source: Ministry of Health/FUNASA/CENEPI
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cidence in this country was virtually
nil; in 1997, when notification became
compulsory, 32,825 cases of rubella
and only 17 cases of congenital ru-
bella syndrome (CRS) were confirmed.
Considering the difficulty in confirm-
ing CRS diagnosis, one can argue that
this information surely underestimates
its importance. In 1999 and 2000 an
epidemic of rubella broke out, with a
high percentage of the cases being di-
agnosed in women in fertile age and
so a national vaccination campaign
was launched against rubella for this
group. The number of CRS cases in
1999, 2000 and 2001 was 39, 79 and
39 respectively. Probably, these num-
bers underestimate the real importance
of rubella in Brazil because of the
many difficulties involved in making
a diagnosis of CRS. There is no na-
tional record for the number of mumps
and chickenpox cases and we should
note that case notification for many
diseases do not reflect their actual in-
cidence, due to the large number of
oligosymptomatic or asymptomatic
cases and to the difficulties in estab-
lishing etiological diagnosis22,23.
Information on meningitis caused
by Haemophilus influenzae was scarce
until the early 1990’s; the largest
number of Hib meningitis cases in Bra-
zil (1,684) was registered in 1995. The
vaccine against Hib was introduced
into the national immunization calen-
dar in the latter part of 1999, inicially
only for children less then 24 month;
during that year the number of Hib
meningitis cases was 1,368, dropping
to 577 in 2001 and to 234 in 2001.
In the year 2000, respiratory dis-
eases were the second cause of hospi-
talization in Brazil (16.2%). Although
the main causes of hospitalization for
respiratory disease are ascribed to
pneumonia, caused by S. pneumoniae,
H. influenzae, influenza virus and Res-
piratory Syncytial Virus, we do not
have information available on the in-
cidence of these infections.
Vaccines routinely recommended
for pregnant women
Vaccines recommended for preg-
nant women should be little
reactogenic, safe for mother and fetus
and capable of inducing a good re-
sponse of class IgG1 antibodies. Ide-
ally, vaccine components should be
specific, highly purified and a single
dose should be sufficient to obtain
high antibody titers. In order to obtain
a suitable transfer of antibodies to the
fetus, the minimum interval between
vaccine administration and childbirth
should be two weeks1-10.
Although several vaccines have
been investigated for use in pregnant
women, currently few vaccines are
routinely recommended, as shown in
table 21.
Vaccines against diphtheria and
tetanus1,2
The best example of the effective-
ness of vaccinating pregnant women is
the reduced number of cases of neo-
natal tetanus in the past decade. In
1989, the World Health Organization
set out to eliminate neonatal tetanus
between 1995 and 2000. With an in-
crease in vaccine coverage a substan-
tial reduction in cases of neonatal teta-
nus was actually observed. However,
over 400,000 cases of neonatal tetanus
are estimated to occur worldwide,
most occuring in developing coun-
tries, where vaccine coverage is poor
and neonatal tetanus accounts for 23
to 73% of deaths during the neonatal
period27.
Tetanus and diphtheria toxoids are
undoubtedly safe, immunogenic and
capable of stimulating the production
of significant amounts of antibodies in
pregnant women, inducing protection
for both mother and baby1-10,25-27.
In Brazil, 296 cases of neonatal
tetanus were notified in 1990 and the
number of cases dropped to 41 and 34
in 2000 and 2001, respectively23. Most
cases of neonatal tetanus result from
failure to vaccinate, as 2 doses of
antitetanus vaccine administered no
later than 6 weeks before childbirth
protect both mother and fetus, even if
the pregnant woman has not received
a previous dose of the vaccine 1,22,23,27.
Table 2 - Vaccination of pregnant women.
Routinely Recommended Vaccines to be indicated only in Vaccines under investigation Contra-indicated vaccines
Vaccines special situations
Adult combined (dT) Against poliomyelitis (oral or inactivated) Pneumo conjugate Measles
Tetanus and diphtheria toxoids Pneumococcal polysaccharide  (Pn23-valent) Meningo conjugate Mumps
Influenza Menigococcal polysaccharide Acellular pertussis Rubella
Yellow fever Group B streptococcus Chickenpox
Hepatitis A Respiratory syncytial virus BCG
Hepatitis B Parainfluenza-3
Rabies Herpes simplex
Japanese encephalitis Attenuated vaccine against
influenza
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Pregnant women who are not vac-
cinated, or are only partially vacci-
nated against tetanus (< three doses)
should receive at least 2 doses of the
antitetanus vaccine (T) or the adult
combined vaccine (dT) at a minimum
one-month interval in between, prefer-
ably after the first trimester of preg-
nancy and at least fifteen days prior to
childbirth. Pregnant women who have
been vaccinated with 3 or more doses
of antitetanus vaccine and have re-
ceived a booster dose within the past
5 years do not need to be vaccinated.
For those who have not received a
booster dose, or received the last dose
more than 5 years ago, administration
of 1 dose of antitetanus vaccine (T) or
adult combined (dT) is recommended
at least 2 weeks prior to childbirth1,22,23.
Vaccine against influenza
Pregnant women and children less
than 1 year of age face a high risk of
complications associated with the in-
fluenza virus. In pregnant women in
the third trimester of pregnancy the
risk of complications is higher than in
young adults who present risk condi-
tions 28-35.
Vaccines against influenza contain
dead viruses or subunits, thus being
non-infectious. Vaccines containing
subunits only are highly purified and
little reactogenic, still they are not rec-
ommended for children under 6
months due to their low immuno-
genicity. For the first vaccination chil-
dren between 6 and 36 months old
should receive 2 doses of the vaccine1.
Thus, in the first year of life, even
when vaccinated, children are highly
vulnerable to infections by the influ-
enza virus33.
Since the late 1970’s, it has been
demonstrated that babies with high
titers of antibodies against the influ-
enza virus in the cord blood have pre-
sented low rates of infection during
epidemic outbreaks; therefore, vacci-
nation of pregnant women could ben-
efit both mother and child 29,30. A study
conducted in Houston between 1975
and 1977 has shown a positive corre-
lation between titers of neutralizing
antibodies in the cord blood and pro-
tection against the strain of influenza
A/Victoria virus, since none of the chil-
dren who presented antibody titers
above 1:8 in the cord blood against
this strain was infected by the influ-
enza virus in the first 8 weeks of life29.
Administration of inactivated
vaccines against influenza to pregnant
women is safe and, in comparison to
the population, pregnant women pro-
duce similar antibody titers; passive
protection conferred on the children of
vaccinated pregnant women persists
for at least 2 months (half-life from 35
to 50 days)29-31.
In the United States, the vaccine
against influenza is recommended for
pregnant women expected to be in the
second or third trimester of pregnancy
when circulation of the influenza vi-
rus is at its peak, and for those who
present a risk condition, irrespective of
the stage of pregnancy 33. This recom-
mendation is based on information re-
lating to vaccine safety during all stages
of pregnancy and on the absence of ad-
verse events for the child28-35.
The advantages of vaccinating
pregnant women against influenza in-
clude mother’s protection at a time
when the risk of complications is at its
highest, reduction in the potential of
a mother who, upon contracting the
infection, transfers it to her child in the
first months of life, and the transfer of
antibodies to the fetus, conferring pas-
sive protection in the first weeks of life.
Although it is difficult to estimate the
duration of passive protection, the
half-life of antibodies acquired pas-
sively is estimated to be of 21 days, yet
it is possible that this protection could
be extended for much longer25-29.
Vaccines recommended for
pregnant women in special
situations only
Vaccines against poliomyelitis
Oral or injectable vaccines against
poliomyelitis are highly immunogenic
and effective for poliomyelitis preven-
tion. In the fifties, they were largely
used by American pregnant women
due to the high risk of infection by the
wild virus. There was no confirmation
of serious adverse events in pregnant
women or their babies36,37. More re-
cently, due to poliomyelitis outbreaks
in Finland, more than 3,000 pregnant
women were given the oral vaccine
against polio, again demonstrating the
safety of such vaccine 12. In 1988 an
epidemic of poliomyelitis caused by
poliovirus type 1 broke out in Israel;
in October 1988 all individuals less
than 40 years old (including pregnant
women) received the oral vaccine
against poliomyelitis. No adverse ef-
fects were reported in vaccinated preg-
nant women or in their offspring, and
an analysis of 88 newborns weighing
more than 2,500 g revealed a transfer
of antibodies against poliovirus type
1 and 2; the titers against the poliovi-
rus type 3 were low 37.
So far there is no evidence that the
vaccines (oral or injectable) against
poliomyelitis cause unwanted effects
for the pregnant woman or the fe-
tus1,9,12.
In Brazil, since 1980, mass vacci-
nation campaigns against polio-
myelites have led to elimination of the
disease in the country. No case of po-
lio has been reported in the past dec-
ade. Since the risk of poliomyelitis is
currently very low, maternal immuni-
zation is not recommended 22,23.
Only in special circumstances
should pregnant women receive oral
vaccine against poliomyelitis. For ex-
ample, non-immune pregnant women
who are expected to go to areas where
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the wild virus still causes endemic dis-
ease (some African regions and the
Southeast of Asia) should be vacci-
nated against polio1,22,23.
Vaccines against hepatitis B
Breast-feeding babies infected by
the hepatitis B virus are at a high risk
of becoming chronic carriers of the
HBs antigen (HBsAg). The vaccine
against hepatitis B is highly purified,
safe and effective, inducing a high rate
of protection among children and
adults (> 90%). Although it is not rou-
tinely recommended for maternal im-
munization, neither pregnant women,
inadvertently vaccinated, nor their ba-
bies presented adverse effects after ad-
ministration of the vaccine and/or spe-
cific immunoglobulin (HBIG) 1,38-40.
A study of 37 pregnant women
vaccinated against hepatitis B during
pregnancy showed that all newborns
from mothers who had developed an-
tibody titers against the HBs antigen
above 1:35 mUI/ml exhibited titers,
considered as being protective, in the
cord blood (above 1:10 mUI/ml) 39. In
another study, 49% (39 out of 80)
pregnant women vaccinated against
hepatitis B presented seroconversion;
this percentage is low; however, most
of them had received 1 or 2 doses of
the vaccine. Obese pregnant women,
smokers or over 25s presented lower
antibody titers than younger, non-
obese and non-smoking women40.
The doses and scheme recom-
mended for the prophylaxis of preg-
nant women after exposure to the hepa-
titis B virus are the same as those rec-
ommended for the population1,38-40.
In Brazil, up until 1998 the vaccine
against hepatitis B was only available
for high-risk groups and few women in
fertile age were vaccinated22,23. There-
fore, we consider it essential to conduct
specific serology for hepatitis B dur-
ing the prenatal period, since, if the
mother is an HBsAg carrier, the new-
born will have to receive immuno-
prophylaxis within the first 12 hours
of life (vaccine + specific immu-
noglobulin). If the pregnant woman is
HBsAg negative, she will have to be
vaccinated during pregnancy only if
she belongs to a risk group for hepati-
tis B1.
Since the risk of contracting the
disease is high among adolescents and
many pregnant adolescents will go
through new pregnancies, it is recom-
mended that pregnant adolescents who
are seronegative for hepatitis B be
vaccinated after childbirth. The vac-
cine against hepatitis B is available for
the entire population less than 20
years old22,23.
Vaccine against hepatitis A
The vaccines against hepatitis A
contain dead viruses and are not infec-
tious; they are highly purified, effec-
tive and induce long-lasting protec-
tion. It is believed that they are not
harmful to pregnant women or the fe-
tus; however, since only recently have
they been licensed and are not much
used routinely, there is little informa-
tion regarding their safety for pregnant
women. The risk of vertical transmis-
sion of hepatitis A is low, therefore the
vaccine is not recommended for preg-
nant women.
In cases where post-exposure
prophylaxis is needed, normal human
immunoglobulin is recommended
within 15 days of exposure, and the
same schemes and doses as recom-
mended for the population apply. If the
pregnant non-immune woman intends
to travel to highly endemic regions for
longer than 5 months, the vaccine may
be administered concurrently with the
immunoglobulin, in separate parts1,9,41.
Vaccines against yellow fever
Yellow fever is a rare disease in in-
dustrialized countries 42; however, in
Brazil the wild form is still endemic in
several parts of the country 22. As death
rates are very high and no specific
treatment is available for this disease,
the vaccine against yellow fever has
been included in the national vaccina-
tion calendar, from 9 months of age,
with booster doses every 10 years. This
recommendation is valid for nearly the
entire national territory (except for a
few states in the South and South-
east)22,23.
The vaccines against yellow fever
contain live attenuated viruses and so
they are not routinely recommended
for pregnant women, except when they
reside in risk areas1,42-44.
Many pregnant women unaware of
their condition were inadvertently
vaccinated against yellow fever,
whether in endemic regions or during
vaccination campaigns. Luckily, to-
date, no serious adverse effects have
been confirmed in the pregnant women
and/or fetuses1,43,44.
Although the vaccine is considered
safe for both pregnant woman and fe-
tus, whenever possible it is recom-
mended that pregnant women plan-
ning a journey to risk areas should
postpone their trip. If this is not possi-
ble, the vaccine should be adminis-
tered at least two weeks before the
pregnant woman travels to risk
areas1,22,42-44.
Polysaccharide vaccine against
pneumococcus
The 23-valent vaccine is recom-
mended only for individuals who face
risk (patients with chronic diseases,
with anatomic or functional asplenia,
old-aged and immunodepressed peo-
ple) and are over 2 years old. Since this
vaccine is highly purified, safe and
immunogenic among adults, it can be
administered to pregnant women in
risk groups. Since a lot of women only
have access to health services during
the prenatal and delivery period, in
such instances it should be checked
whether the use of pneumococcal poly-
saccharide vaccine is indicated1,45-51.
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Some authors evaluated the re-
sponse of pregnant women to polysac-
charide vaccines against the pneumo-
coccus and the results from all studies
indicated that these vaccines are safe
and capable of inducing immunologic
response. In addition to protecting
pregnant women, they are likely to
protect the baby passively through
transplacental crossing of antibodies
and transfer of antibodies through the
colostrum and maternal milk45-51.
Polysaccharide vaccines against
meningococci
Polysaccharide vaccines against A,
C, Y and W135 groups meningococci
are recommended only in risk situa-
tions. They are highly purified and
immunogenic vaccines, and they of-
fered no risk for vaccinated pregnant
women nor did they affect response to
vaccination in babies whose mothers
had been vaccinated during preg-
nancy. Although the crossing of anti-
bodies from mother to fetus is variable,
in addition to conferring protection on
the pregnant woman, the vaccines can
afford increased immunity on the new-
born1.52-54.
New perspectives: vaccines under
investigation
During the neonatal period, the
group B streptococcus and enterobac-
teria account for most bacterial infec-
tions and, in the first few months of
life, babies are very vulnerable to in-
vasive infections by encapsulated bac-
teria such as Haemophilus influenzae
type b, Streptococcus pneumoniae and
N. meningitidis1-10. The quest for safe
and effective vaccines for these agents
has been very successful, particularly
with the development of conjugate
vaccines against the Hib, pneumococ-
cus and meningococcus, already li-
censed in several countries55.
Despite the success, young breast-
feeding babies remain at a high risk of
contracting these infections, since
multiple doses of conjugate vaccines
are required. Vaccination of pregnant
women against these agents is consid-
ered a valid alternative to offer protec-
tion to babies in the first few weeks of
life56. Although little has been studied
about vaccination of pregnant women
with new conjugate vaccines against
Hib, pneumococcus and menin-
gococcus, results from studies pub-
lished in the past decade are very
promising2-10.
Conjugate vaccines against Hib
Hib invasive diseases usually affect
young babies and, since the eighties,
the role of polysaccharide vaccines
against Hib in pregnant women has
been studied, with the purpose of reduc-
ing the impact of the disease on breast-
feeding infants. Pregnant women re-
spond well to polysaccharide vaccines
and studies have shown that they are
safe both for pregnant woman and fe-
tus, besides demonstrating that there is
a passive transfer of antibodies through
the placenta and the maternal milk56-62.
Conjugate vaccines against Hib are ca-
pable of inducing production of class
igG1 antibodies in titers higher than
those obtained from non-conjugate
vaccines. In some studies, antibody
titers against the Hib found in the cord
blood were higher than maternal titers,
suggesting active transfer of such anti-
bodies. We should note that the anti-
bodies transferred through the placenta
do not affect immunological response
to the vaccine administered after six
weeks of life58-62.
After conjugate vaccines against
the Hib were incorporated into na-
tional immunization programs and in-
vasive diseases by this bacterium were
virtually eliminated, their indication
for pregnant women became very lim-
ited. Still, studies involving these
vaccines are considered excellent
models for the study of other vaccines
in pregnant women9,56-62.
Conjugate vaccines against S.
pneumoniae
S. pneumoniae is the main agent
for pneumonia in almost every age
group; it is among the 3 main agents
causing bacterial meningitis, besides
causing several types of infection, e.g.
acute otitis media, sinusitis, bacteremia
and sepsis, among others1,5,14.
Today more than 90 S. pneumoniae
serotypes are recognized, however, be-
cause cross immunity among different
serotypes is low, the prevention of dis-
eases caused by the pneumococcus re-
quires polyvalent vaccines 1.
Children under two years of age
constitute a high-risk group for serious
infections caused by the S.
pneumoniae; however, the 23-valent
polysaccharide vaccine is only recom-
mended for high-risk groups over two
years old due to its low immuno-
genicity in breast-feeding infants1.
A new conjugate vaccine contain-
ing seven pneumococcus serotypes
has been licensed recently. It is recom-
mended for breast-feeding infants over
six weeks old49. Despite being ex-
tremely safe, immunogenic and very
effective against serious forms of the
disease, the 7-valent conjugate vac-
cine is expensive and its scope of pro-
tection is limited to the serotypes con-
tained in the vaccine. Since it is nec-
essary to administer 3 doses of the
vaccine, at 2, 4 and 6 months, up un-
til the sixth month of life, children less
than six months are only partially pro-
tected. A large percentage of the cases
of invasive disease caused by pneumo-
coccus occur in breast-feeding infants
less than 6 months old, so it is essen-
tial to look for new alternatives of pre-
vention for diseases caused by this
bacterium. Polysaccharide vaccines
against the pneumococcus adminis-
tered to pregnant women in the third
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trimester of pregnancy are safe for
mother and fetus and, theoretically,
they could confer some degree of pro-
tection on newborns45-47.
In comparison to polysaccharide
vaccines, conjugate vaccines are more
immunogenic and capable of reducing
the number of S. pneumoniae carriers.
It is possible that the vaccination of
pregnant women with these new
vaccines should afford higher antibody
titers in babies, conferring extended
protection; however, their scope of pro-
tection is limited. As yet we do not
know whether the new pneumococcal
conjugate vaccines administered to
pregnant women and to breast-feeding
infants will have an impact on collec-
tive immunity. We should remember that
the number of S. pneumoniae serotypes
capable of causing invasive diseases
and disease of mucous membranes is
much higher than that of H. influenzae,
which is almost exclusively restricted
to the Hib9,10.
Vaccines against group B
streptococci
The group B streptococcus (GBS) is
among the most important pathogen in
the neonatal period and in children less
than three months old 1,63-65. It is esti-
mated that the incidence of serious dis-
eases caused by the GBS is 3 out of
1,000 living newborns. In the USA
alone, every year 11,000 cases of sep-
sis or meningitis by the GBS are re-
ported. GBS accounts for 2,500 deaths
every year and although 1,350 children
survive, they are left with serious after
effects 65. Besides attacking young ba-
bies, the GBS causes enormous morbid-
ity in pregnant women, and is one of the
main agents of urinary infections,
chorioamnionitis, endometritis and in-
fections from surgical wounds in the pu-
erperium. Despite recommendations for
the use of prophylactic antibiotics in
risk groups, the disease still has a high
incidence and is very serious63-65.
Studies conducted in the 1970´s
established a relationship between an-
tibody deficiency against the GBS’s
polysaccharide capsule in pregnant
women and the susceptibility of both
mother and fetus to infections. In the
1980´s, polysaccharide vaccines
against the group B streptococcus were
tested in pregnant women, with prom-
ising results. Although the vaccines
containing polysaccharides from the
GBS capsule were safe, the immuno-
logical response against the different
types of GBS varied 63-65.
Immuno-protective response - de-
fined as reaching antibody titers above
1 mcg/ml, 4 weeks after vaccination -
was achieved in approximately 40%
of those vaccinated against type Ia,
88% against type II and 60% against
type III, indicating the need for more
immunogenic vaccines63-65.
Later on, with the technology of
conjugate vaccines, vaccines contain-
ing the GBS polysaccharide capsule´s,
conjugated with tetanus toxoid against
several GBS serotypes (Ia Ib, II, III)
were developed. These new vaccines
are highly immunogenic and safe, both
in animals and in adult volunteers, and
they should be useful for pregnant
women; however, the development of
conjugate vaccines against the GBS is
hindered by the number of pathogenic
serotypes. It is thus necessary to de-
velop multivalent vaccines against
several serotypes (Ia Ib, II, III and V).
Conjugate vaccines against
serotypes III and V are currently under-
going clinical tests, and their safety
and immunogenicity have already
been demonstrated in adults, including
women of childbearing potential. Con-
jugate vaccines for use in animal mod-
els are currently undergoing tests in
order to evaluate fetus protection66.
Acellular vaccines against
whooping cough
In developed countries, where
vaccines against the whooping cough
have been largely used for over 40
years, the disease persists as an impor-
tant cause of morbidity, especially
among young babies. In the United
States, Canada and several countries in
Europe there has been an increase in
the number of whooping cough cases,
with a deviation of the age group with
the highest incidence of the disease.
Today 25% to 35% of the cases are di-
agnosed in adolescents and adults.
These individuals are the main reser-
voirs of the B. pertussis and several
cases were documented where the
mother, grandparents or health care
professionals were to account for the
transmission of the disease to babies.
Most complications, hospitalizations
and deaths from whooping cough oc-
cur in the first six months of life, a
time when the child is still unprotected
against the disease, despite vaccina-
tion1,67,68. In Brazil, all 27 whooping
cough deaths registered in the year
2000 occurred in children less than
one year old23.
Since the forties, the role of anti-
bodies against B. pertussis for disease
protection has been known and, in the
fifties, pregnant women vaccinated
against whooping cough were noted
to transfer their antibodies to the fe-
tus68. Nonetheless, whole cell vaccines
against whooping cough are not rec-
ommended after 7 years of age due to
their reactogenicity 1. Recent develop-
ment of acellular vaccines against the
whooping cough - already licensed for
children and adults - has prompted dis-
cussion over their indication for ado-
lescents, adults and perhaps pregnant
women, in order to boost protection
against this serious disease1,67,68.
Other vaccines
Several vaccines against other
agents that cause serious infections in
young children are being developed.
Vaccines containing live attenuated
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viruses against influenza, rotavirus,
respiratory syncytial virus, herpes sim-
plex and parainfluenza are now under-
going advanced testing stages in
adults and children. If they prove safe
for these age groups, they may then be
tested in pregnant women to protect
newborns indirectly2-10,69,70.
Vaccines contraindicated during
pregnancy
Vaccines against tuberculosis, mea-
sles, mumps, rubella and chickenpox
are contraindicated for pregnant
women, it being advisable that women
in fertile age should avoid pregnancy
during the month following vaccina-
tion71-79.
It is possible that these vaccines are
safe during pregnancy; the results from
studies conducted in the United States
and Canada involving more than 400
pregnant women inadvertently vacci-
nated against rubella are reassuring be-
cause of the absence of cases of con-
genital rubella syndrome; however,
these numbers are not sufficient to en-
sure that the vaccine will not cause
any harm to the fetus74.
From March 17, 1995 to March 16,
2000, 362 pregnant women were ex-
posed to the vaccine against chicken-
pox in the United States; 92 were se-
ronegative and 58 received the vaccine
in the first trimester of pregnancy.
None of the 56 newborns presented
any type of malformation. Due to the
small number of cases studied, it was
not possible to ensure that the vaccine
is exempt of risks for pregnant woman
and fetus79.
Where non-immune pregnant
women are exposed to measles or
chickenpox, passive immuno-prophy-
laxis is recommended1,80.
CONCLUSIONS
In addition to increasing mother
protection, the vaccination of pregnant
women is an excellent opportunity to
confer protection on babies by trans-
ferring antibodies passively, whether
through the placenta or through
breast-feeding. All current evidences
are indicative that the vaccines which
do not contain live agents and the
immunoglobulins being currently
recommended for adults are safe and
immunogenic for pregnant women and
that, even vaccines containing live at-
tenuated viruses, e.g. yellow fever, oral
polio and rubella, do not pose risks for
the fetus. However, before one can rec-
ommend large-scale use, new studies
involving a sufficient number of
mother-baby pairs are necessary so as
to assure the absence of risks for preg-
nant women and babies. We should
mention that, during pregnancy, the
vaccination scheme against diphtheria
and tetanus should be updated; it is
also essential to identify pregnant
women in risk groups - who should be
vaccinated against influenza and pneu-
mococcus - as well as to check whether
the pregnant woman was suitably im-
munized against rubella and hepatitis
B. Children whose mothers are HBsAg
carriers should receive vaccine and
specific immunoglobulin, preferably
within the first 24 hours of life, and
those in the puerperium period who are
non-immune to hepatitis B or rubella
should be vaccinated against these
diseases at that time.
It is expected that in the near fu-
ture the vaccine calendar for pregnant
women will be widely expanded, with
new vaccines being incorporated.
RESUMO
BRICKS LF - Vacinação em gestantes:
considerações sobre sua importân-
cia no Brasil. Rev. Hosp. Clín. Fac.
Med. S. Paulo 58 (5):263-274,
2003.
Recém-nascidos e lactentes jovens
permanecem vulneráveis a diversas
doenças causadas por vírus e bactéri-
as. Em geral, as estratégias de imuni-
zação são inefetivas para que a crian-
ça produza anticorpos em quantidades
suficientes nos primeiros seis meses de
vida. Gestantes podem produzir anti-
corpos IgG que são transportados ati-
vamente através da placenta e podem
beneficiar tanto a mãe quanto a crian-
ça. Entretanto, com poucas exceções,
as vacinas não são recomendadas roti-
neiramente para as gestantes, devido
às preocupações relacionadas à segu-
rança desse procedimento. A realização
de estudos para avaliar os riscos e be-
nefícios da vacinação em gestantes
implica em dificuldades éticas e cul-
turais, tendo baixa aceitação.
Na última década, o desenvolvi-
mento de vacinas, muito seguras e
imunogênicas, reativou o debate sobre
os riscos e benefícios da vacinação de
gestantes, particularmente, quando
existe alto risco de a gestante e/ou o
feto apresentarem infecção com graves
conseqüências.
Neste trabalho, apresentamos uma
revisão da literatura sobre a imuniza-
ção em gestantes, utilizando dados do
MEDLINE (1990-2002).
Conclusões: 1) não existem evi-
dências de risco para o feto quando a
gestante é imunizada com toxóides,
vacinas polissacarídicas, conjugadas
ou contendo vírus mortos; 2) provavel-
mente, a maioria das vacinas conten-
do vírus atenuados também é segura,
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mas os dados sobre sua segurança ain-
da são insuficientes; 3) no Brasil, é ne-
cessário melhorar a cobertura vacinal
de gestantes contra o tétano.
Novas vacinas são candidatas para
uso em gestantes, porém, é necessário
realizar pesquisas para avaliar sua se-
gurança, eficácia e possíveis indica-
ções, considerando-se dados epide-
miológicos regionais.
DESCRITORES: Vacinas. Gravi-
dez. Imunização materna. Doenças
infecciosas. Neonatal.
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